ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 17

Anti-endothelial cell antibodies in juvenile dermatomyositis

Rie Karasawa1, Mayumi Tamaki1, Toshiko Sato1, Megumi Tanaka1, Kazuo Yudoh2 and James Jarvis3, 1Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki, Japan, 2Institute of Medical Science, St. Marianna University School of Medicine, Kanagawa, Japan, 3Pediatrics, SUNY Buffalo School of Medicine, Buffalo, NY

Meeting: 2017 Pediatric Rheumatology Symposium

Keywords: autoantigens, juvenile dermatomyositis and proteomics

  • Tweet
  • Email
  • Print
Session Information

Date: Thursday, May 18, 2017

Title: Genetics and Pathogenesis Poster Breakout I

Session Type: Abstract Submissions

Session Time: 4:45PM-5:15PM

Background/Purpose:  Juvenile dermatomyositis (JDM) is the most common form of inflammatory myopathy in children. Although classified as a myopathy, involved tissues in JDM are characterized by prominent vascular and perivascular inflammation that are believed to be directly involved in the clinical features of the disease. Thus, JDM also can be characterized as a form of vasculitis. Anti-endothelial cell antibodies (AECA) are detected in multiple autoimmune, infectious, and inflammatory diseases, including vasculitis. We aimed to determine whether such antibodies are present in JDM and, if so, to comprehensively detect their target antigens using a proteomics approach. Methods:  To detect antibodies in sera from patients with JDM, proteins extracted from human aortic endothelial cells (HAEC) were used as antigen sources by SDS-PAGE and immunoblotting. To comprehensively detect target antigens for AECA, we separated proteins extracted from HAEC by two-dimensional electrophoresis (2DE) and then transferred them onto membranes. Autoantigens that were positive only in sera from children with JDM but not in sera from healthy children were detected by western blotting (WB). The detected proteins were then identified by mass spectrometry (MS). Bound IgG antibodies to antigens were detected using standard methods. Results:  Five candidate protein spots as JDM-specific proteins were detected in 2DE-WB. From these spots, we successfully identified 34 proteins which we characterized broadly according to their functions: (1) 62% were ATP-related proteins such as proteins of the tricarboxylic acid (TCA) cycle (e.g., pyruvate kinase PKM and 78kDa glucose-regulated protein; (2) 21% were muscle-related proteins, including myosin-9 and Cdc42-interacting protein 4; (3) 18% were calcium regulated proteins and/or calcium binding proteins (e.g., annexin A6 and N-acetylglucosamine-6-sulfatase). We also identified eight proteins that act as chaperones or co-chaperones in intracellular protein trafficking. Furthermore 22 of the 34 identified antigens represented membrane proteins. Using Ingenuity Pathway Analysis (IPA), 27 of the 34 candidate target antigens for AECA in JDM were predicted to interact with chaperone proteins, which regulate the correct folding, stabilization, and translocation of proteins. Conclusion:  IgG antibodies to proteins in the proteome of HAEC are present in the sera of JDM. The presence of AECA in JDM could implicate these antibodies in the pathobiology of the vascular/perivascular inflammation that is a proment feature of JDM.

Disclosure: R. Karasawa, None; M. Tamaki, None; T. Sato, None; M. Tanaka, None; K. Yudoh, None; J. Jarvis, None.

To cite this abstract in AMA style:

Karasawa R, Tamaki M, Sato T, Tanaka M, Yudoh K, Jarvis J. Anti-endothelial cell antibodies in juvenile dermatomyositis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 4). https://acrabstracts.org/abstract/anti-endothelial-cell-antibodies-in-juvenile-dermatomyositis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-endothelial-cell-antibodies-in-juvenile-dermatomyositis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology